On April 3, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that new interim data from Cohort 2 of the innovaTIL-01 (C-144-01) study and data from the ongoing innovaTIL-04 (C-145-04) study will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting taking place from May 31 to June 4, 2019, in Chicago. Details of the presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1
Authors: Amod Sarnaik et al.
Session: Developmental Immunotherapy and Tumor Immunobiology
Session Type: Poster Discussion Session
Abstract Number: 2518
Location: McCormick Place Convention Center
Date/Time: Poster display Saturday, June 1, 8:00 a.m. – 11:00 a.m. EDT; poster discussion 1:15 p.m. – 2:45 p.m. EDT

Title: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma
Authors: Amir Jazaeri et al.
Session: Developmental Immunotherapy and Tumor Immunobiology
Session Type: Poster Session
Abstract Number: 2538
Location: McCormick Place Convention Center
Date/Time: Saturday, June 1, 8:00 a.m. – 11:00 a.m. EDT